Do you know the patient characteristics of the second trial? Cause I couldn't find that info anywhere. Just gonna trust when they say they "matched" them with a historical control that it's equivalent to stratified randomization? Won't bother to ask how many MGMT methyl? How many with early suspected PD but very long OS (so almost certainly psPD)? No care or idea???
You need to remember that there are more apparent methylated pseudo progressors with DCVax-L so the conclusion is they have magically found a way to skew their numbers. Let's see, about 4%-9% can historically survive to 5 years but now we magically have more than twice that number. Must be all that selection bias and improved surgical resection NWBO utilizes. That is why the NLNK 30 mo. SOC has the shorts licking their lips. What happens if the whole group (treatment and SOC) averages over 36 months OS and only minimal separation between groups? Now that would be really confounding as well as unprecedented.
News 
Market Data 
Discover 
